Page 4 - Nasdaq Ango News Today

AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) – Equities research analysts at Zacks Research lowered their FY2023 EPS estimates for AngioDynamics in a research report issued to clients and investors on Wednesday, April 12th. Zacks Research analyst D. Dey now expects that the medical instruments supplier will earn ($0.06) per share for the year, down from […]

AngioDynamics (NASDAQ:ANGO – Get Rating) and Vivos (OTCMKTS:RDGL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Analyst Recommendations This is a breakdown of current recommendations and price […]

AngioDynamics (NASDAQ:ANGO – Get Rating) had its price target trimmed by Raymond James from $22.00 to $14.00 in a research report report published on Monday, Benzinga reports. The firm currently has a strong-buy rating on the medical instruments supplier’s stock. Separately, StockNews.com initiated coverage on shares of AngioDynamics in a report on Thursday, March 16th. […]

AngioDynamics (NASDAQ:ANGO – Get Rating) had its price objective cut by Raymond James from $22.00 to $14.00 in a report published on Monday morning, Benzinga reports. They currently have a strong-buy rating on the medical instruments supplier’s stock. Separately, StockNews.com assumed coverage on AngioDynamics in a research note on Thursday, March 16th. They issued a […]

AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) – Equities researchers at KeyCorp lowered their Q4 2023 earnings per share estimates for AngioDynamics in a research report issued on Thursday, March 30th. KeyCorp analyst M. Mishan now anticipates that the medical instruments supplier will post earnings of $0.04 per share for the quarter, down from their prior […]

AngioDynamics (NASDAQ:ANGO – Get Rating) had its price target lowered by equities researchers at Raymond James from $22.00 to $14.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has a “strong-buy” rating on the medical instruments supplier’s stock. Raymond James’ price objective would indicate a potential upside […]

AngioDynamics (NASDAQ:ANGO – Get Rating) updated its FY 2023 earnings guidance on Friday. The company provided EPS guidance of -$0.06–$0.01 for the period, compared to the consensus EPS estimate of -$0.01. The company issued revenue guidance of $338.00 million-$342.00 million, compared to the consensus revenue estimate of $342.47 million. Analyst Upgrades and Downgrades A number […]

AngioDynamics (NASDAQ:ANGO – Get Rating) posted its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02), Briefing.com reports. AngioDynamics had a negative net margin of 9.98% and a negative return on equity of 0.14%. The business had revenue of […]

AngioDynamics (NASDAQ:ANGO – Get Rating) posted its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.02), Briefing.com reports. The business had revenue of $80.70 million during the quarter, compared to analysts’ expectations of $83.20 million. AngioDynamics had a negative […]

AngioDynamics (NASDAQ:ANGO – Get Rating) issued an update on its FY 2023 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of -$0.06–$0.01 for the period, compared to the consensus estimate of -$0.01. The company issued revenue guidance of $338.00 million-$342.00 million, compared to the consensus revenue estimate of $342.47 million. […]